1-4 of 4
Milos Dokmanovic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity

Free
Haoheng Yan, Yukinori Endo, Yi Shen, David Rotstein, Milos Dokmanovic, Nishant Mohan, Partha Mukhopadhyay, Bin Gao, Pal Pacher, Wen Jin Wu
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (3): 480–490.
https://doi.org/10.1158/1535-7163.MCT-15-0580
Published: 06 March 2016
View articletitled, Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity
Open the PDF for Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity in another window
Journal Articles

Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance

Free
Milos Dokmanovic, Yi Shen, Tabetha M. Bonacci, Dianne S. Hirsch, Wen Jin Wu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (6): 917–928.
https://doi.org/10.1158/1535-7163.MCT-10-0980
Published: 08 June 2011
View articletitled, Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance
Open the PDF for Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance in another window
Journal Articles

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

Free
Milos Dokmanovic, Dianne S. Hirsch, Yi Shen, Wen Jin Wu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1557–1569.
https://doi.org/10.1158/1535-7163.MCT-09-0140
Published: 10 June 2009
View articletitled, Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
Open the PDF for Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer in another window
Journal Articles

Histone deacetylase inhibitors selectively suppress expression of HDAC7

Free
Milos Dokmanovic, Gisela Perez, Weisheng Xu, Lang Ngo, Cathy Clarke, Raphael B. Parmigiani, Paul A. Marks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (9): 2525–2534.
https://doi.org/10.1158/1535-7163.MCT-07-0251
Published: 17 September 2007
View articletitled, Histone deacetylase inhibitors selectively suppress expression of HDAC7
Open the PDF for Histone deacetylase inhibitors selectively suppress expression of HDAC7 in another window